Munich - Delayed Quote EUR

United Therapeutics Corp (UTH.MU)

Compare
343.80
-13.20
(-3.70%)
As of 8:00:44 AM GMT+1. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
2,756,200.00
2,327,500.00
1,936,300.00
1,685,500.00
1,483,300.00
Cost of Revenue
304,800.00
257,500.00
151,600.00
122,500.00
108,100.00
Gross Profit
2,451,400.00
2,070,000.00
1,784,700.00
1,563,000.00
1,375,200.00
Operating Expense
1,106,900.00
885,100.00
805,000.00
1,007,100.00
781,600.00
Operating Income
1,344,500.00
1,184,900.00
979,700.00
555,900.00
593,600.00
Net Non Operating Interest Income Expense
150,700.00
103,400.00
12,800.00
-1,900.00
5,100.00
Other Income Expense
-57,300.00
-14,000.00
-41,900.00
39,900.00
40,200.00
Pretax Income
1,437,900.00
1,274,300.00
950,600.00
593,900.00
638,900.00
Tax Provision
327,000.00
289,500.00
223,300.00
118,100.00
124,100.00
Net Income Common Stockholders
1,110,900.00
984,800.00
727,300.00
475,800.00
514,800.00
Diluted NI Available to Com Stockholders
1,110,900.00
984,800.00
727,300.00
475,800.00
514,800.00
Basic EPS
24.33
21.04
15.98
10.60
11.65
Diluted EPS
22.76
19.81
15.00
10.06
11.54
Basic Average Shares
45,750.00
46,800.00
45,500.00
44,900.00
44,200.00
Diluted Average Shares
48,875.00
49,700.00
48,500.00
47,300.00
44,600.00
Total Operating Income as Reported
1,279,400.00
1,184,900.00
979,700.00
555,900.00
593,600.00
Total Expenses
1,411,700.00
1,142,600.00
956,600.00
1,129,600.00
889,700.00
Net Income from Continuing & Discontinued Operation
1,110,900.00
984,800.00
727,300.00
475,800.00
514,800.00
Normalized Income
1,161,195.28
984,800.00
728,609.00
477,640.00
522,171.00
Interest Income
200,800.00
162,700.00
45,200.00
16,700.00
28,600.00
Interest Expense
50,100.00
59,300.00
32,400.00
18,600.00
23,500.00
Net Interest Income
150,700.00
103,400.00
12,800.00
-1,900.00
5,100.00
EBIT
1,488,000.00
1,333,600.00
983,000.00
612,500.00
662,400.00
EBITDA
1,554,500.00
1,386,800.00
1,034,300.00
662,400.00
712,300.00
Reconciled Cost of Revenue
304,800.00
257,500.00
151,600.00
122,500.00
108,100.00
Reconciled Depreciation
66,500.00
53,200.00
51,300.00
49,900.00
49,900.00
Net Income from Continuing Operation Net Minority Interest
1,110,900.00
984,800.00
727,300.00
475,800.00
514,800.00
Total Unusual Items Excluding Goodwill
-65,100.00
--
-1,700.00
-2,300.00
-9,100.00
Total Unusual Items
-65,100.00
--
-1,700.00
-2,300.00
-9,100.00
Normalized EBITDA
1,619,600.00
1,386,800.00
1,036,000.00
664,700.00
721,400.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-14,804.72
--
-391.00
-460.00
-1,729.00
12/31/2020 - 2/29/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ANEB Anebulo Pharmaceuticals, Inc.
1.5900
+2.58%
 
TYRA Tyra Biosciences, Inc.
14.71
+0.41%
 
PVLA Palvella Therapeutics, Inc.
13.50
+1.43%
 
FENC Fennec Pharmaceuticals Inc.
6.55
+1.24%
 
MLYS Mineralys Therapeutics, Inc.
10.27
-0.87%
 
GBIO Generation Bio Co.
0.8128
-5.44%
 
KALV KalVista Pharmaceuticals, Inc.
8.77
0.00%
 
ZURA Zura Bio Limited
1.7600
+1.73%
 
RZLT Rezolute, Inc.
5.21
+2.96%
 
VRDN Viridian Therapeutics, Inc.
20.08
+3.35%